References
- Epstein E, Goedel A. Hamorrhagische thrombozythamie bei vascularer schrumpfmilz [Hemorrhagic thrombocythemia with a vascular, sclerotic spleen]. Virchows Archiv A Pathol Anat Histopathol 1934; 293: 233
- Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951; 6: 372–375
- Gunz F W. Hemorrhagic thrombocythemia: a critical review. Blood 1960; 15: 706–723
- Fialkow P J, Faguet G B, Jacobson R J, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981; 58: 916–919
- Murphy S, Iland H, Rosenthal D, Laszlo J. Essential thrombocythemia: an interim report from the polycythemia vera study group. Semin Hematol 1986; 23: 177–182
- Vardiman J W, Brunning R D, Harris N L. WHO histological classification of chronic myeloproliferative diseases. World Health Organization Classification of Tumors: Tumours of the Haematopoietic and Lymphoid Tissues, E S Jaffe, N L Harris, H Stein, J W Vardiman. International Agency for Research on Cancer (IARC) Press, Lyon 2001; 17–44
- Thiele J, Kvasnicka H M. A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders. Leuk Lymphoma 2006; 47: 381–396
- Gianelli U, Vener C, Rafaniello Raviele P, Moro A, Savi F, Annaloro C, et al. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology. Leuk Lymphoma 2006; 47: 1774–1781
- Kantarjian H M, Bueso-Ramos C E, Talpaz M, O'Brien S, Giles F, Rios M B, et al. The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. Leuk Lymphoma 2005; 46: 993–997
- Tefferi A, Pardanani A. Mutation screening for JAK2 (V617F): when to order the test and how to interpret the results. Leuk Res 2006, doi: 10.1016/j.leukres.2006. 01.004